| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Rudi Beyaert | Q37382622 |
| P2093 | author name string | Isabelle Carpentier | |
| Inna S Afonina | |||
| Lynn Elton | |||
| P2860 | cites work | A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue | Q22010675 |
| CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B | Q24291024 | ||
| I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity | Q24298219 | ||
| Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation | Q24298225 | ||
| Phosphorylation of the CARMA1 linker controls NF-kappaB activation | Q24298828 | ||
| IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis | Q24300707 | ||
| T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20 | Q24307779 | ||
| ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB | Q24336707 | ||
| The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes | Q24338639 | ||
| NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation | Q24652716 | ||
| Structural determinants of MALT1 protease activity | Q27677492 | ||
| Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase | Q27685382 | ||
| Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation | Q28115331 | ||
| Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation | Q28189327 | ||
| Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction | Q28198772 | ||
| CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members | Q28201693 | ||
| The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination | Q28201717 | ||
| Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency | Q28204372 | ||
| Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway | Q28206030 | ||
| Regulation and function of IKK and IKK-related kinases | Q28268930 | ||
| Dectin-1: a signalling non-TLR pattern-recognition receptor | Q28286159 | ||
| A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions | Q28287278 | ||
| MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression | Q28305065 | ||
| Differential Requirement for Malt1 in T and B Cell Antigen Receptor Signaling | Q28505229 | ||
| The MAGUK family protein CARD11 is essential for lymphocyte activation | Q28511124 | ||
| Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay | Q28588318 | ||
| Regulation of NF-κB-Dependent Lymphocyte Activation and Development by Paracaspase | Q28591729 | ||
| The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses | Q29616349 | ||
| Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. | Q33958556 | ||
| Mechanism and specificity of the human paracaspase MALT1. | Q34151837 | ||
| Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation | Q34161140 | ||
| T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. | Q34174201 | ||
| Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. | Q34211312 | ||
| Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. | Q34277639 | ||
| Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation | Q34346617 | ||
| Requirement for caspase-8 in NF-kappaB activation by antigen receptor. | Q34399988 | ||
| MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes | Q34432953 | ||
| Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation | Q34441762 | ||
| Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. | Q34457270 | ||
| The proteolytic activity of the paracaspase MALT1 is key in T cell activation | Q34748769 | ||
| Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. | Q34806889 | ||
| NF-κB signaling pathways regulated by CARMA family of scaffold proteins | Q35347919 | ||
| Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity | Q35964742 | ||
| A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency | Q36979888 | ||
| Multifunctional roles for MALT1 in T-cell activation. | Q37198925 | ||
| CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes | Q37448141 | ||
| MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo | Q37699271 | ||
| A20: from ubiquitin editing to tumour suppression | Q37728850 | ||
| Regulation of NF-κB signaling by caspases and MALT1 paracaspase | Q37814066 | ||
| Non-canonical NF-κB signaling pathway | Q37822660 | ||
| A20-mediated negative regulation of canonical NF-κB signaling pathway | Q38163423 | ||
| A20 in inflammation and autoimmunity | Q38163677 | ||
| Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation. | Q39134494 | ||
| The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. | Q39193083 | ||
| Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. | Q39226671 | ||
| Cleavage by MALT1 induces cytosolic release of A20. | Q39661717 | ||
| Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells | Q39785748 | ||
| A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. | Q39843043 | ||
| Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity | Q40422412 | ||
| Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation | Q41240873 | ||
| The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells | Q41522425 | ||
| Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation | Q41629410 | ||
| The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation | Q43119003 | ||
| MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation | Q44750362 | ||
| Combined immunodeficiency associated with homozygous MALT1 mutations | Q45734660 | ||
| Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination | Q46118529 | ||
| MALT lymphoma: from morphology to molecules | Q57369685 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | NF-κB | Q411114 |
| soldier | Q4991371 | ||
| P304 | page(s) | 3286-3297 | |
| P577 | publication date | 2015-05-21 | |
| P1433 | published in | FEBS Journal | Q1388041 |
| P1476 | title | MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression | |
| P478 | volume | 282 |
| Q26765188 | API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis |
| Q58761499 | Age-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma: An Approach |
| Q58777266 | CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis |
| Q39056717 | Differing Requirements for MALT1 Function in Peripheral B Cell Survival and Differentiation |
| Q92798453 | GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein |
| Q47645620 | Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. |
| Q36364264 | Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach |
| Q92021823 | Impact of co-blocking the costimulatory signals on immune-related genes after high-risk rabbit corneal allograft using 2nd-generation DNA sequencing technology |
| Q59353657 | Inhibition of MALT1 decreases neuroinflammation and pathogenicity of virulent rabies virus in mice |
| Q39443989 | Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome |
| Q41625334 | MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage |
| Q93047664 | MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner |
| Q48103382 | MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling |
| Q47549174 | MALT1 controls attenuated rabies virus by inducing early inflammation and T cell activation in the brain. |
| Q37327533 | MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation |
| Q92669067 | MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types |
| Q60924644 | Mepazine Inhibits RANK-Induced Osteoclastogenesis Independent of Its MALT1 Inhibitory Function |
| Q39215807 | MicroRNA-649 promotes HSV-1 replication by directly targeting MALT1. |
| Q41919605 | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Positively Modulates Matrix Metalloproteinase-9 Production in Alveolar Macrophages upon Toll-Like Receptor 7 Signaling and Influenza Virus Infection |
| Q41717303 | Mucosa-associated lymphoid tissue lymphoma translocation 1 as a novel therapeutic target for rheumatoid arthritis |
| Q47119181 | Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma |
| Q34521887 | Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation. |
| Q57072726 | The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex |
| Q55302804 | The Direct and Indirect Roles of NF-κB in Cancer: Lessons from Oncogenic Fusion Proteins and Knock-in Mice. |
| Q46718859 | The FEBS Journal in 2016: read, reflect and don't feed the wolves. |
| Q47853157 | The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion |
| Q59792572 | Treatment of Dextran Sulfate Sodium-Induced Colitis with Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Inhibitor MI-2 Is Associated with Restoration of Gut Immune Function and the Microbiota |
| Q36239551 | Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation |
| Q52538370 | Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.